Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Interest & Investment Income (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Interest & Investment Income data on record, last reported at $26.6 million in Q1 2026.

  • On a quarterly basis, Interest & Investment Income fell 19.2% to $26.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $113.4 million, a 6.49% decrease, with the full-year FY2025 number at $119.7 million, up 8.84% from a year prior.
  • Interest & Investment Income reached $26.6 million in Q1 2026 per PCVX's latest filing, up from $26.5 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for PCVX hit a ceiling of $36.5 million in Q4 2024 and a floor of $134000.0 in Q1 2022.
  • A 5-year average of $19.3 million and a median of $21.7 million in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: soared 7655.97% in 2023, then decreased 27.45% in 2025.
  • Tracing PCVX's Interest & Investment Income over 5 years: stood at $6.6 million in 2022, then skyrocketed by 164.86% to $17.6 million in 2023, then surged by 107.53% to $36.5 million in 2024, then fell by 27.45% to $26.5 million in 2025, then increased by 0.6% to $26.6 million in 2026.
  • Business Quant data shows Interest & Investment Income for PCVX at $26.6 million in Q1 2026, $26.5 million in Q4 2025, and $29.3 million in Q3 2025.